Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood-Reference-Cited by-同舟云学术

Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood

Published:1998-11 Issue:9142 Volume:352 Page:1731-1738
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

van Dongen Jacques JM,Seriu Taku,Panzer-Grümayer E Renate,Biondi Andrea,Pongers-Willemse Marja J,Corral Lilly,Stolz Frank,Schrappe Martin,Masera Giuseppe,Kamps Willem A,Gadner Helmuth,van Wering Elisabeth R,Ludwig Wolf-Dieter,Basso Giuseppe,de Bruijn Marianne AC,Cazzaniga Giovanni,Hettinger Klaudia,van der Does-van den Berg Anna,Hop Wim CJ,Riehm Hansjörg,Bartram Claus R

Publisher

Elsevier BV

Subject

General Medicine

Reference34 articles.

1. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86;Reiter;Blood,1994

2. High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia: results of protocol ALL. VI from the Dutch Childhood Leukemia Study Group;Veerman;J Clin Oncol,1996

3. Collaborative Group. Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: overview of 42 trials involving 12000 randomised children;Childhood;Lancet,1996

4. Detection of minimal residual disease in acute leukemia by immunological marker analysis and polymerase chain reaction;Van Dongen;Leukemia,1992

5. Detection of minimal residual leukemia by the polymerase chain reaction: potential implications for therapy;Bartram;Clin Chim Acta,1993

Cited by 825 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Are measurable residual disease results after consolidation therapy useful in children with acute lymphoblastic leukemia?;Leukemia;2024-09-10

2. High-Throughput Sequencing Revealing BCR and TCR Repertoires as Potential Prognostic Biomarkers for Pediatric Patients with B-ALL;Current Genomics;2024-08-21

3. Looking ahead to CD3, T-cell engager bispecific antibodies for hematological malignancies;Expert Opinion on Biological Therapy;2024-07-29

4. MIR4435-2HG as a possible novel predictive biomarker of chemotherapy response and death in pediatric B-cell ALL;Frontiers in Molecular Biosciences;2024-04-30

5. The Evolving Landscape of Flowcytometric Minimal Residual Disease Monitoring in B-Cell Precursor Acute Lymphoblastic Leukemia;International Journal of Molecular Sciences;2024-04-30